Monitoring insulin-like growth factors in HIV infection and AIDS.
There is a close association between the growth hormone (GH)-insulin-like growth factor I (IGF-I) axis, infection and immunity. Infection with the human immunodeficiency virus (HIV) is often associated with a decrease of the concentrations of IGF-I, IGF-II, IGF-binding protein 3 (IGFBP-3) and an increase of IGFBP-1 and -2. Many investigators have studied the relationship between the GH-IGF-I system and some of the most common characteristics of disease progression, such as decreased CD4 cell counts, weight loss and fat redistribution. Although conditions for restoration of thymic function and lymphopoiesis with GH or IGF-I are still not well defined, many studies led to the development of clinical trials on the therapeutic use of GH, IGF-I and GHRH for the treatment of weight loss or fat redistribution, two problems which persist despite the introduction of highly active antiretroviral therapy. Monitoring IGF-I concentrations during treatment with GH and GHRH is likely to become an essential component of their therapeutic use. IGF-I levels are the first indicator of treatment efficacy and can be used to monitor compliance. High levels of IGF-I are a warning sign for the increased risk of potential adverse effects, such as acromegalic-like symptoms or malignancy. This could lead to a reduction of the therapeutic dose or the temporary interruption of treatment until IGF levels reach a safe range. IGF-I levels are also likely to increase with other hormones used in HIV patients, such as erythropoietin for the treatment of anemia or anabolic androgens in HIV-infected women.
Congote
Luis F
LF
Endocrine Laboratory, Rm. L2.05, McGill University Health Centre, Montreal, Québec, Canada H3A 1A1. luis.f.congote@muhc.mcgill.ca
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D000728:Androgens / Q000097:blood; D004921:Erythropoietin / Q000097:blood; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D013002:Somatomedins / Q000276:immunology / Q000378:metabolism*
D000728:Androgens; D013002:Somatomedins; D004921:Erythropoietin